samedan logo
 
 
spacer
home > ict > winter 2017 > survey time
PUBLICATIONS
International Clinical Trials

Survey Time

For drug developers, the transition from traditional, 100% source document verification (SDV) to risk-based monitoring (RBM) strategies requires a sweeping transformation in clinical trial operations. RBM impacts everything Ė from trial design and data management platforms to the roles and skillsets of clinical project teams. Effective change management can identify barriers to implementing RBM, inform the development of training programmes and guide interventions to overcome obstacles among operations teams.

It has been found that incorporating surveys of clinical trial managers (CTMs) and clinical research associates (CRAs) is an effective way to gauge adoption progress and to refine change management processes.

New Mindset

PPD has conducted more than 150 RBM trials since late 2013. Early experience has shown that implementing risk-based approaches necessitates new ways of thinking and executing trials.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
As Executive Director of AIM at PPD, Nicole Stansbury leads the development and implementation of the organisationís RBM strategy. She holds a Bachelorís degree in Animal Science from Texas A&M University, US.
spacer
Nicole Stansbury
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

TheVax Genetics Vaccine CO., Ltd and Biotechpharma UAB to collaborate on cGMP production of THEVAX HBV Vaccine

VILNIUS, Lithuania and TAIPEI, Taiwan, April 30, 2018 /PRNewswire/ -- TheVax Genetics Vaccine CO., Ltd (6567.TWO) and Biotechpharma UAB have entered into a manufacturing agreement to produce THEVAX HBV vaccine for first-in-human clinical trials.
More info >>

White Papers

Migration safe pharmaceutical labels improve patient safety

UPM Raflatac

Labels play an invaluable role on pharmaceutical packages. Pharmaceutical companies should only use labels that meet low-leachability and extraction requirements. Labels that are not migration safe, e.g. create leachable chemical compounds, may fail testing and result in significant launch delays or costly recalls. This white paper presents how pharmaceutical companies can ensure that the final label constructions achieve their business, regulatory and patient safety goals.
More info >>

 
Industry Events

SMiís 9th Annual Biosimilars & Biobetters Conference

25-27 September 2018, Copthorne Tara Hotel, London, UK

Following the success of our previous events in both London and the US, Biosimilars and Biobetters UK 2018, SMi deliver a stellar speaker line-up and bring together a global audience of biosimilar experts to discuss the latest developments and future of the rapidly evolving and expanding biosimilars market.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement